Edurant (rilpivirine) / J&J - LARVOL DELTA

Deltoid Administration of LAI-ART: Pharmacokinetic Implications When the Gluteal Site Is Not Feasible. (PubMed, Infez Med) - "Specifically, it focuses on intensive pharmacokinetic monitoring following deltoid administration of LAI rilpivirine and cabotegravir in a 29-year-old transgender woman with progressive multifocal leukoencephalopathy and swallowing difficulties...By day 10, the patient's clinical condition had deteriorated, leading to hospice care and subsequent death. Rilpivirine exposure after deltoid injection appeared lower than that typically reported after gluteal or thigh administration, although intracellular drug concentrations may differ from plasma levels, potentially mitigating clinical concerns."

Journal • PK/PD data • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Rare Diseases

Preclinical evaluation of long-acting cabotegravir and rilpivirine for HIV post-exposure prophylaxis in a macaque model. (PubMed, EBioMedicine) - "We document protection in macaques by one-time CAB LA/RPV LA PEP under highly stringent modeling conditions. Delayed breakthrough infections highlight potential diagnostic challenges associated with this PEP modality and underscore the need for prolonged follow-up."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease

Long-Acting Cabotegravir/Rilpivirine for HIV Antiretroviral Therapy Throughout Pregnancy: A Case Report and Literature Review. (PubMed, Case Rep Infect Dis) - "Benefits of CAB/RPV during pregnancy include improved drug adherence and discretion. Based on our experience and review of the literature, long-acting intramuscular CAB/RPV may be of value in treatment-experienced patients experiencing difficulties with pill adherence."

Journal • Cardiovascular • CNS Disorders • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Nephrology • Ventriculomegaly

Sterile abscesses following administration of long-acting injectable rilpivirine for HIV. (PubMed, BMJ Case Rep) - "We describe a case of a young adult with sterile abscesses at the sites of two consecutive injections. This case describes a significant side effect noted during post-market roll-out."

Journal • Human Immunodeficiency Virus • Infectious Disease

Impact of Gluteal Injection Site on Pharmacokinetics and Tolerability of Antiretroviral Therapy with Long-Acting Cabotegravir and Rilpivirine. (PubMed, AIDS Patient Care STDS) - "Ventrogluteal administration is associated with more consistent pharmacokinetics and improved tolerability, supporting its use as the preferred site for long-acting CAB/RPV. Although CAB trough levels were modestly lower and occasionally fell below predefined thresholds with VG injection, this did not impact virologic outcomes, reinforcing its clinical suitability in most settings."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease

The safety of cabotegravir in pregnancy: a systematic review and meta-analysis. (PubMed, BMC Infect Dis) - "The small sample size currently precludes a definitive conclusion on the safety profile of cabotegravir use during pregnancy. More research in this area is required to assess this drug's role in utero."

Journal • Retrospective data • Review • Human Immunodeficiency Virus • Infectious Disease

Co-amorphous Approach for Enhancing Rilpivirine Oral Bioavailability using CYP3A4 Inhibitor as a Co-former. (PubMed, AAPS PharmSciTech) - "Stability studies confirmed CAMS maintained its amorphous state for over three months, as shown by DSC, PXRD, FE-SEM, solubility and dissolution studies. The CAMS of rilpivirine and nicotinamide, prepared through solvent evaporation at 1:1 molar ratio, enhanced rilpivirine's solubility, dissolution, permeation, and oral bioavailability, offering a promising antiretroviral drug delivery strategy."

Journal • Human Immunodeficiency Virus • Infectious Disease • CYP3A4

Giant B cell Cardiac Lymphoma Presenting as SVC Syndrome: An unusual presentation of an unusual diagnosis (AHA 2025) - "It primarily affects immunocompetent adults, with a median age of 55–65 years, and male predominance (65–85%).Case Presentation A 44-year-old male with well-controlled HIV on Rilpivirine presented with a 2-week history of progressive shortness of breath, facial edema, and exertional peripheral cyanosis. Standard treatment for primary cardiac DLBCL involves immunochemotherapy, most commonly R-CHOP unless contraindicated. Curative regimens yield 5-year survival rates of 70–80% in selected cohorts; however, prognosis worsens with advanced or extracardiac disease."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • High-grade B-cell lymphoma • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma

Cabotegravir and Rilpivirine concentrations and HIV-1 RNA suppression in genital fluids and rectum in people with HIV on long-acting intramuscular Cabotegravir plus Rilpivirine antiretroviral therapy. (PubMed, J Infect Dis) - P4 | "This study examined cabotegravir (CAB) and rilpivirine (RPV) distribution and HIV suppression in genital and rectal compartments after switching to long-acting intramuscular CAB+RPV administered every two months. All participants maintained HIV-1 RNA <20 copies/mL in all matrices. Clinical Trial Registration: EudraCT Number: 2021-006779-41."

Journal • Human Immunodeficiency Virus • Infectious Disease

Exploring the Interaction Between Injection Site and Biological Sex on the Real-world Population Pharmacokinetics of Long-acting Cabotegravir and Rilpivirine in People With HIV. (PubMed, Open Forum Infect Dis) - "Subcutaneous depot deposition after intramuscular injections is not uncommon, occurring more frequently in females and is associated with increased skin to muscle thickness. Slower absorption of cabotegravir from subcutaneous administration contributes to the observed sex differences in drug concentrations."

Journal • PK/PD data • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Minimal impact of pregnancy on rilpivirine pharmacokinetics in women living with HIV. (PubMed, Int J Infect Dis) - "In our study, no significant effect of pregnancy on rilpivirine pharmacokinetic parameters was reported. No dose adjustment for orally administered rilpivirine should be recommended in this setting."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease

Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/ emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study. (PubMed, J Infect Chemother) - P3 | "Switching to CAB+RPV LA OLI demonstrated comparable efficacy to continuing BIC/FTC/TAF, was well tolerated and preferred by most participants who switched. ClinicalTrials.gov; NCT04542070 (https://clinicaltrials.gov/study/NCT04542070)."

Journal • P3 data • Human Immunodeficiency Virus • Infectious Disease

Integrating HIV and Mental Health Care in Prison: A Complex but Achievable Goal (EACS 2025) - "ART regimens were predominantly INSTI-based (67%, mainly dolutegravir and bictegravir), with 15% on NNRTI-based regimens (doravirine, rilpivirine), 9% on PI-based (DRV/b), and 9% on mixed regimens. However, the high burden of psychiatric disorders, substance use, and comorbidities necessitates integrated, multidisciplinary management. Special attention to drug interactions and post-release continuity of care is essential to maintain long-term health outcomes."

Hepatitis B • Hepatitis C • Human Immunodeficiency Virus • Infectious Disease • CD4

IMPACT OF PREEXISTING K103N ON THE EFFECTIVINES OF LA-CAB+RPV: REAL-LIFE RELATIVITY COHORT (EACS 2025) - "Purpose : K103N is a nonpolymorphic NNRTI resistance-associated mutation (RAM) selected in people with HIV (PWH) treated with nevirapine (NVP) or efavirenz (EFV). It reduces susceptibility to NVP and EFV by approximately 50-fold and 20-fold, respectively, but does not affect susceptibility to rilpivirine (RPV), etravirine (ETR), or doravirine (DOR)...BASELINE CHARACTERISTICS REGARDING THE PRESENCE OF K103N Conclusions : The presence of the K103N mutation was not associated with an increased risk of virological failure in PWH treated with LA-CAB+RPV. These findings suggest that a history of K103N should not preclude the use of this regimen."

Clinical • Human Immunodeficiency Virus • Infectious Disease

Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide from NNRTI-based ART in virologically suppressed people with HIV (PWH): a retrospective analysis (DRIVE-SWITCH study) (EACS 2025) - "Purpose : Large real-world data in people with HIV (PWH) switching from non-nucleoside reverse transcriptase inhibitors (NNRTIs), especially from rilpivirine (RPV)-based regimens to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) are lacking...Results : Overall, 250 PWH were included: median age 59 years (interquartile range, IQR 51-65); 65 (26%) females at birth, 213 (85%) Italian natives; 141 (56%) switched from RPV/FTC/TAF, 7 (2.8%) from RPV/FTC/TDF, 96 (38.4%) from EFV/FTC/TDF, 3 (1.2%) from NVP+TDF/FTC, 2 (0.8%) from DOR/3TC/TDF, 1 (0.4%) from NVP+TAF/FTC...Treatment discontinuations were rare events. No resistance mutations detected."

Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Using Nanopore sequence data to analyse drug resistance profile and its association with phylodynamics from HIV quasispecies (EACS 2025) - "Some 170 quasispecies were flagged with NNRTI DRMs, the only rilpivirine-associated mutation found was V179 in 54 (32%) quasispecies...Sociodemographic and epidemiological factors were not associated with phylodynamic characteristics. Conclusions : The results evidenced the emergence risk of DRMs from a longer history of in vivo mutation, signifying the importance of early diagnosis and rapid treatment initiation."

Human Immunodeficiency Virus • Infectious Disease

High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon. (PubMed, J Antimicrob Chemother) - "The high level of resistance found in this study, coupled with the identification of DRMs either in circulating and archived viruses, only suggests that a comprehensive profiling of DRMs in both viral populations would provide additional information for adolescents with a detectable viremia."

Journal • Human Immunodeficiency Virus • Infectious Disease

In vitro modulation of adipocyte differentiation by tenofovir alafenamide/disoproxil fumarate following challenge with recent ARV drugs. (PubMed, Cell Cycle) - "However, the effects of non-nucleoside-reverse-transcriptase-inhibitors (NNRTIs) and of the novel long-acting INSTI cabotegravir (CAB), on adipogenesis, alone or in combination with NRTIs or other INSTIs, remain unclear...The NNRTIs doravirine (DOR) and rilpivirine (RPV) were tested alone and in combination with DTG, CAB, TDF, TAF...Finally, NNRTIs and INSTIs promote adipogenesis and induce fibroblastic features in 3T3-L1 cells. Contrarily, TAF and TDF exhibited an antagonistic effect on adipogenesis when combined with certain antiretrovirals, supporting our previous research."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease • CEBPA • PPARG

Persistence on dolutegravir-containing two- and three-drug-regimens in clinical practice. (PubMed, Int J STD AIDS) - "All people with HIV-1 receiving DTG-containing ART regimens-combined with rilpivirine (RPV) or lamivudine (3TC) for 2DRs, or with tenofovir (TAF or TDF) and emtricitabine (FTC), or abacavir (ABC) and FTC for 3DRs-were included. However, the study's retrospective nature and center-specific characteristics may limit generalizability. More real-world data are warranted to confirm these results."

Journal • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease • CD4

Discovery and molecular docking studies of nitrogen containing naphthyridine derivatives as potent HIV1 NNRTIs with anticancer potential. (PubMed, Sci Rep) - "Among them, 2-cyanopyridinyl-1,6-naphthyridines 16a, 16b, and 19a showed stronger activity than nevirapine (IC50 = 1.053 µM) with IC50 values of 0.222, 0.218, and 0.175 µM, comparable to rilpivirine (0.063 µM) and efavirenz (0.058 µM). Additionally, naphthyridines 16a, 16b, and 19a displayed no toxicity toward normal embryonic lung cells (MRC-5). Thus, 2,4-disubstituted-1,6- and 1,7-naphthyridines could serve as promising HIV-1 RT inhibitors."

Journal • Cervical Cancer • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Leukemia • Oncology • Solid Tumor

Real-World Experience with Long-Acting Injectable Cabotegravir/Rilpivirine in HIV Patients with Unsuppressed Viral Load. (PubMed, Viruses) - "We present a case series of eight PWH treated at two tertiary centers in Italy, all of whom faced persistent viremia, adherence difficulties, malabsorption syndromes, or psychosocial barriers. Following the switch to CAB/RPV-LA, all patients, despite heterogeneous clinical profiles and baseline virological status, achieved and maintained virologic suppression, demonstrated improved adherence, and experienced no serious adverse events."

Journal • Real-world evidence • Gastrointestinal Disorder • Human Immunodeficiency Virus • Infectious Disease

Breastfeeding on ART and a closer look at drug transfer to HIV-exposed uninfected infants. (PubMed, Sci Rep) - "Maternal ART regimens included abacavir/lamivudine (n = 2), tenofovir alafenamide/emtricitabine (n = 1) or tenofovirdisoproxil/emtricitabine (n = 5) in combinations with rilpivirine (n = 3) (RPV), dolutegravir (n = 2) (DTG), raltegravir (n = 1), darunavir/ritonavir (n = 1), or nevirapine (n = 1). Given this variability and the potential for drug accumulation in individual cases, maternal therapeutic drug monitoring should be considered to identify elevated levels early on. In such situations, infant monitoring tailored to the individual may also be warranted."

Journal • Retrospective data • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Neutropenia

Evaluating birth outcomes following oral rilpivirine use in pregnancy in the United States: Findings from the antiretroviral pregnancy registry. (PubMed, HIV Med) - "Review of available data from the APR does not indicate an association between adverse pregnancy or birth outcomes and oral-RPV exposure, overall or by timing of exposure. Since APR targets primarily teratogenic effects, findings for non-teratogenic effects should be interpreted with caution."

Journal • Human Immunodeficiency Virus • Infectious Disease

Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors. (PubMed, Acta Pharm Sin B) - "Furthermore, this analog exhibited minimal adverse effects with significantly reduced cytotoxicity (CC50 = 195 μmol/L) and a high selectivity index (SI = 102,608), superior to those of etravirine (CC50 > 4.6 μmol/L, SI > 1436) and rilpivirine (CC50 = 3.98 μmol/L, SI = 3989). Additionally, A12 exhibited favorable oral bioavailability (F = 29.2%) and an extended elimination half-life (T 1/2 = 13.56 h), enabling convenient oral administration at minimal doses. These findings indicated that A12 could serve as a promising drug candidate for HIV treatment."

Journal • Human Immunodeficiency Virus • Infectious Disease

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (clinicaltrials.gov) - P1/2 | N=168 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease